Valuation: Decoy Therapeutics Inc.

Market Cap 1.16M 1.03M 962K 877K 1.65M 111M 1.67M 11.64M 4.51M 56.99M 4.35M 4.26M 183M P/E 2026 *
-0.2x
P/E 2027 * -0.21x
Enterprise Value 1.16M 1.03M 962K 877K 1.65M 111M 1.67M 11.64M 4.51M 56.99M 4.35M 4.26M 183M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.57%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Decoy Therapeutics Inc.

1 day-4.58%
1 week-42.72%
Current month-10.15%
1 month-34.20%
3 months-75.79%
6 months-69.48%
Current year-77.27%
1 week 1.61
Extreme 1.61
2.38
1 month 1.61
Extreme 1.61
7.61
Current year 1.61
Extreme 1.61
16.92
1 year 1.61
Extreme 1.61
55.92
3 years 1.61
Extreme 1.61
1,339.2
5 years 1.61
Extreme 1.61
35,459.97
10 years 1.61
Extreme 1.61
533,353.97
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Free

Founder

33,455 5.1062%
8/31/26 Free

Chief Financial Officer

9,682 1.4778%
8/31/26 Free

Director

2,000 0.3053%
Change 5-day change 1-year change 3-year change Capi.($)
-4.58%-42.72%-96.21%-99.81% 1.16M
+4.16%+3.04%+49.37%+94.17% 74.16B
+1.35%-2.08%+21.65%+81.32% 57.39B
+1.33%-1.68%+3.09%+36.79% 47.64B
+0.36%+0.81%+342.39%+748.97% 44.29B
-0.96%-4.50%+24.96%+31.45% 42.5B
-0.20%-0.77%+4.13%+111.69% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+3.75%+31.90%+29.14% 28.53B
+0.05%-1.64%-8.14%-12.10% 24.34B
Average +0.19%-4.80%+38.25%+107.57% 39.05B
Weighted average by Cap. +1.05%-0.84%+57.47%+139.99%

Financials

2026 *2027 *
Net sales - -
Net income -10.1M -8.97M -8.38M -7.63M -14.4M -971M -14.53M -101M -39.28M -496M -37.92M -37.1M -1.59B -19.1M -16.97M -15.84M -14.44M -27.23M -1.84B -27.48M -192M -74.28M -939M -71.71M -70.15M -3.01B
Net Debt - -
Logo Decoy Therapeutics Inc.
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Employees
11
Date Price Change Volume
26-10-02 US$1.770 -4.58% 255,622
26-10-01 US$1.855 -5.84% 169,452
26-09-30 US$1.970 -7.51% 238,032
26-09-29 US$2.130 -7.79% 712,322
26-09-28 US$2.310 -25.24% 549,739
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.770USD
Average target price
3.000USD
Spread / Average Target
+69.49%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DCOY Stock